Drugs / (N1, N3-bis(2- mercaptoethyl)isophthalamide)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04183595 | Nov 2023 → May 2024 | mercury poisoning | EmeraMed | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (N1, N3-bis(2- mercaptoethyl)isophthalamide) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04183595 ↗ |
| Known as | NBMI | “NBMI (N1, N3-Bis (2-Mercaptoethyl) Isophthalamide)” NCT04183595 ↗ |
| Route | Oral | “with an oral dose of 600 mg” NCT04183595 ↗ |